ÿþ<HTML><HEAD><TITLE>Bristol Myers Squibb Company - Securities Class Action</TITLE> <META NAME='DESCRIPTION' CONTENT='<b>Summary:</b> According to a press release dated June 8, 2006, the Securities and Exchange Commission announced that $750 million will be distributed to compensate shareholders injured by fraudulent earnings management at Bristol-Myers Squibb Company (BMS). The distribution fund includes $150 million BMS paid to settle fraud charges brought by the Commission. The fund also includes $300 million BMS paid to settle a related civil class action, and $300 million paid by BMS in a deferred prosecution agreement with the U.S. Attorney's Office in New Jersey to address the company's criminal liability. Recent orders entered by federal courts in New Jersey and New York allowed for the coordinated distribution. On Aug. 4, 2004, without admitting or denying the allegations in the Commission's complaint, BMS consented to be permanently enjoined from violating certain provisions of the federal securities laws. The company also agreed to remedial measures and to pay $150 million to compensate investors. By distributing the money under a single distribution plan, administrative costs are substantially reduced. In a press release dated June 5, 2005, pharmaceutical company Bristol-Myers Squibb Co. is expected to settle a federal probe of its past accounting practices for $300 million, according to published reports. As part of the so-called "deferred prosecution" agreement, the New York-based company would be able to avoid criminal charges if it complies with certain terms of the settlement, The New York Times and The Wall Street Journal both reported Sunday night on their Web sites, citing unnamed sources familiar with the settlement talks. An announcement of the agreement could come this week, the reports said. Among the terms of the deal with the Justice Department are expected to be the separation of the chairman and chief executive titles currently held by Peter R. Dolan, and other changes in the company's corporate governance practices, according to the Journal. No current Bristol-Myers Squibb executives are expected to be indicted, thought it's possible former executives may be indicted, according to the Journal. In a press release dated July 30, 2004, the Lead Plaintiffs in this case announced that the court has granted preliminary approval of a settlement reached in the securities class action litigation. Bristol-Myers Squibb Company has agreed to pay $300 million to the Class Members. The settlement resolves all of the Class Members' claims against the company and the individual defendants. Bristol-Myers said in a statement that the company had agreed to a separate settlement of $150 million with the Securities and Exchange Commission without admitting or denying any liability, and company executives would not comment on any other investigations into its accounting practices or the future steps it might take. On April 2, 2004, the Court entered the Order granting the motion to dismiss the action. The plaintiffs soon after filed a Notice of Appeal. On July 30, 2004, the Second Circuit Court of Appeals issued a Mandate remanding the action to the District Court for purposes of settlement, and on August 4, 2004, a Stipulation and Order of Settlement was filed. In 2000, class action was filed Bristol Myers Squibb Company in the US District Court for the District of New Jersey. According to the docket for this 2002 case, on October 7, 2002, the Court issued a Stipulation and Order granting the motion to transfer claims and the complaints containing only Vanlev claims to the USDC for the District of New Jersey. All non-Vanlev cases and all non-Vanlev claims, including all such claims alleged in the complaint in the actions pending in the USDC for Southern District of New York were ordered to remain in the Southern District of New York. The Class Members were allegedly damaged by the artificial inflation of Bristol Myers's stock price due to the defendants' materially false and misleading statements and omissions regarding the company's financial condition and the prospect for the U.S. Food and Drug Administration's approval of the drug Erbitux, in which Bristol-Myers invested $2 billion for the drug's development. More specifically, the original complaint alleges that defendants violated the federal securities laws by making itself, and allowing its drug development partner to make, without correction, materially false and misleading statements about the progress of its Erbitux cancer treatment drug's application for FDA approval even as BRISTOL-MYERS knew that the application and data were false. Specifically, the complaint alleges that on December 28, 2001, a press release disclosed that the FDA had rejected the filing of a Biologics License Application for Erbitux. On January 4, 2002, The Cancer Letter reported that the FDA repeatedly informed defendants about problems with the Erbitux clinical trials during the Class Period. These shocking revelations caused the stock to plummet from a Class Period high of $56 to $40 by March of 2002.'> <META NAME='KEYWORDS' CONTENT='Bristol Myers Squibb Company - Securities Class Action, Class Action, Securities'></HEAD> <BODY background='/img/bg.gif' VLINK=#660000 ALINK=#DDDDDD LINK=#330066> <TABLE WIDTH=765> <TR><TD WIDTH=151><IMG SRC='/img/frond2.gif'></TD> <TD ALIGN='left'> <table width='600' border='0' cellspacing='0' cellpadding='0'> <tr> <td height='75'><img src='/img/scac_banner_600.jpg' width='600' height='85' usemap='#MapMapMap' border='0'><map name='MapMapMap'><area shape='rect' coords='338,56,591,77' href='http://www.cornerstone.com'><area shape='rect' coords='7,4,232,36' href='http://www.law.stanford.edu/'></map></td> </tr> <tr bgcolor='#330066'> <td height='35'> <table width='600' border='0' cellspacing='6' cellpadding='0' bgcolor='#330066' height='20'> <tr bgcolor='#330066'> <td height='20' width='297'><font face='Garmond,Helvetica,Times' size=4 color=#330066><b><font color='#FFFFFF'>Company and Case Information</font></b></font></td> <td height='20' width='285'> <div align='right'><b><font face='Garmond, Helvetica, Times' size='1' color='#660000'><font color='#FFFFFF'><font face='Garmond,Helvetica,Times'> </font></font><a href='##' onClick='window.open ('/warning/disclaimer.htm', 'avance', 'toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=no, resizable=no,valign=middle,align=center,width=480,h eight=465');'><font color='#FFFFFF'>IMPORTANT INFORMATION</font></a><font color='#FFFFFF'> | <a href='/search.shtml'><font color='#FFFFFF'></font></a></font><a href='/companies.html'><font color='#FFFFFF'>INDEX OF FILINGS</font></a><font color='#FFFFFF'> | <a href='/search.shtml'><font color='#FFFFFF'>SEARCH</font></a></font><font color='#FFFFFF'><a href='/search.shtml'></a></font><font color='#FFFFFF'><a href='/search.shtml'></a></font></font></b></div> </td> </tr> </table> </td> </tr> </table> </TD></TR> <TR><TD VALIGN='top'> <table width='136' border='0' cellspacing='7' cellpadding='0' height='558'> <tr valign='top' bgcolor='#330066'> <td height='770'> <p><font size='2' color='#000000'><font size='3' color='#FFFFFF'><a href='/index.html'><font face='Garmond,Helvetica,Times' color='#FFFFFF'>Home<br> <br> </font></a><a href='/companies.html'><font face='Garmond,Helvetica,Times' color='#FFFFFF'>Index of Filings</font></a><a href='/decisions.html'><font face='Garmond,Helvetica,Times'> </font></a><br> </font></font><br> <font size='3' color='#000000'><font color='#FFFFFF'><font size='3'><a href='/news.html'><font face='Garmond, Helvetica, Times' color='#FFFFFF'>News and Press Releases</font></a></font><br> </font></font><font size='3' color='#000000'><font color='#FFFFFF'><br> <a href='/filing.html'><font face='Garmond,Helvetica,Times' color='#FFFFFF'>Filings</font></a></font></font></p> <p><font size='3' color='#000000'><font color='#FFFFFF'><a href='/decisions.html'><font face='Garmond,Helvetica,Times' color='#FFFFFF'>Decisions</font></a></font></font></p> <p><font size='3' color='#000000'><font color='#FFFFFF'><a href='/research.html'><font face='Garmond,Helvetica,Times' color='#FFFFFF'></font></a></font><font size='3' color='#000000'><font color='#FFFFFF'><a href='/settle.html'><font face='Garmond,Helvetica,Times' color='#FFFFFF'>Settlements<br> </font></a></font></font></font></p> <p><font size='3' color='#000000'><font color='#FFFFFF'> </font></font><font size='3' color='#000000'><font color='#FFFFFF'><a href='/litigation_activity.html'><font face='Garmond,Helvetica,Times' color='#FFFFFF'>Litigation Activity Indices</font></a><br> </font></font></p> <p><font size='3' color='#000000'><font size='3' color='#000000'><font color='#FFFFFF'><a href='/top_ten_list.html'><font face='Garmond,Helvetica,Times' color='#FFFFFF'>Top Ten List</font></a></font></font></font></p> <p><font size='3' color='#000000'><font color='#FFFFFF'><a href='/annual_quarterly_updates.html'><font face='Garmond,Helvetica,Times' color='#FFFFFF'>Annual/Quarterly Updates</font></a> </font></font><font size='3'><br> <br> <font color='#000000'><font color='#FFFFFF'><a href='/clearinghouse_research.html'><font face='Garmond,Helvetica,Times' color='#FFFFFF'>Clearinghouse Research</font></a> </font></font><br> <a href='/news.html'><font face='Garmond, Helvetica, Times' color='#FFFFFF'><br> </font></a></font><font size='3' color='#000000'><font color='#FFFFFF'><a href='/research.html'><font face='Garmond,Helvetica,Times' color='#FFFFFF'>Articles & Papers</font><br> </a><a href='/lr.html'> <font face='Garmond,Helvetica,Times' color='#FFFFFF'> <br> </font></a><a href='/search.shtml'><font face='Garmond,Helvetica,Times' color='#FFFFFF'>Search</font></a> <br> <a href='/sites.html'><font face='Garmond,Helvetica,Times' color='#FFFFFF'><br> Related Sites</font></a><a href='/sponsor.html'><font face='Garmond,Helvetica,Times'><br> </font></a></font></font></p> <p><font size='3' color='#000000'><font color='#FFFFFF'><a href='/email.html'><font size='3' color='#000000'><font color='#FFFFFF'></font></font></a><font size='3' color='#000000'><font color='#FFFFFF'><a href='/lr.html'><font size='3' color='#000000'><font color='#FFFFFF'></font></font></a><font size='3' color='#000000'><font color='#FFFFFF'><a href='/email.html'><font size='3' color='#000000'><font color='#FFFFFF'></font></font></a><font size='3' color='#000000'><font color='#FFFFFF'><a href='/info.html'><font face='Garmond,Helvetica,Times' color='#FFFFFF'>About Us<br> </font></a><a href='/search.shtml'><font face='Garmond,Helvetica,Times' color='#FFFFFF'></font></a></font></font><font face='Garmond,Helvetica,Times' color='#FFFFFF'></font></font></font><br> <a href='/lr.html'><font face='Garmond,Helvetica,Times' color='#FFFFFF'>Local Rules</font></a><br> <a href='/info.html'><font face='Garmond,Helvetica,Times' color='#FFFFFF'><br> </font></a></font></font><a href='/sponsor.html'><font face='Garmond,Helvetica,Times' color='#FFFFFF'>Sponsors</font></a></font><a href='/sponsor.html'><font face='Garmond,Helvetica,Times'><br> </font></a></font><br> <font size='3' color='#000000'><font color='#FFFFFF'><a href='/email.html'><font face='Garmond,Helvetica,Times' color='#FFFFFF'>Register</font></a></font></font></p> <p><font color='#000000'><img src='/img/nullbar.gif' width='120' height='8'></font><br> <font face='Garmond,Helvetica,Times' size='1' color='#FFFFFF'><b>_______________<br> </b></font><font face='Garmond,Helvetica,Times' size='1' color='#FFFFFF'><b>Copyright (c) 2001<br> Stanford Law School </b></font> </p> </td> </tr> </table> </TD><TD valign='top'><br><font FACE=Garmond,Helvetica,Times size=4 color=#330066><B> Bristol Myers Squibb Company</B><font size=2> <form method='get' action='http://find.stanford.edu/search'> <input type='text' name='q' size='40' maxlength='255' value=''/> <font face='Garmond,Helvetica,Times' size=2 color=#330066><b><font size=1> <input type='submit' name='btnG' value='SEARCH CASE COURT FILINGS'/> </font></b></font> <input type='hidden' name='site' value='stanford'/> <input type='hidden' name='client' value='stanford'/> <input type='hidden' name='proxystylesheet' value='http://google.stanford.edu/stylesheet.xslt'/> <input type='hidden' name='output' value='xml_no_dtd'/> <input type='hidden' name='as_dt' value='i'/> <input type='hidden' name='as_sitesearch' value='http://securities.stanford.edu/1023/BMY02-01'> </form> </font></font> <font FACE=Garmond,Helvetica,Times size=2 color=#330066> <b>Conclusion:</b>&nbsp;According to a press release dated June 8, 2006, the Securities and Exchange Commission announced that $750 million will be distributed to compensate shareholders injured by fraudulent earnings management at Bristol-Myers Squibb Company (BMS). The distribution fund includes $150 million BMS paid to settle fraud charges brought by the Commission. The fund also includes $300 million BMS paid to settle a related civil class action, and $300 million paid by BMS in a deferred prosecution agreement with the U.S. Attorney's Office in New Jersey to address the company's criminal liability. Recent orders entered by federal courts in New Jersey and New York allowed for the coordinated distribution. On Aug. 4, 2004, without admitting or denying the allegations in the Commission's complaint, BMS consented to be permanently enjoined from violating certain provisions of the federal securities laws. The company also agreed to remedial measures and to pay $150 million to compensate investors. By distributing the money under a single distribution plan, administrative costs are substantially reduced. <br><br> In a press release dated June 5, 2005, pharmaceutical company Bristol-Myers Squibb Co. is expected to settle a federal probe of its past accounting practices for $300 million, according to published reports. As part of the so-called "deferred prosecution" agreement, the New York-based company would be able to avoid criminal charges if it complies with certain terms of the settlement, The New York Times and The Wall Street Journal both reported Sunday night on their Web sites, citing unnamed sources familiar with the settlement talks. An announcement of the agreement could come this week, the reports said. Among the terms of the deal with the Justice Department are expected to be the separation of the chairman and chief executive titles currently held by Peter R. Dolan, and other changes in the company's corporate governance practices, according to the Journal. No current Bristol-Myers Squibb executives are expected to be indicted, thought it's possible former executives may be indicted, according to the Journal. <br><br> In a press release dated July 30, 2004, the Lead Plaintiffs in this case announced that the court has granted preliminary approval of a settlement reached in the securities class action litigation. Bristol-Myers Squibb Company has agreed to pay $300 million to the Class Members. The settlement resolves all of the Class Members' claims against the company and the individual defendants. Bristol-Myers said in a statement that the company had agreed to a separate settlement of $150 million with the Securities and Exchange Commission without admitting or denying any liability, and company executives would not comment on any other investigations into its accounting practices or the future steps it might take. <br><br> On April 2, 2004, the Court entered the Order granting the motion to dismiss the action. The plaintiffs soon after filed a Notice of Appeal. On July 30, 2004, the Second Circuit Court of Appeals issued a Mandate remanding the action to the District Court for purposes of settlement, and on August 4, 2004, a Stipulation and Order of Settlement was filed. <br><br> In 2000, class action was filed Bristol Myers Squibb Company in the US District Court for the District of New Jersey. According to the docket for this 2002 case, on October 7, 2002, the Court issued a Stipulation and Order granting the motion to transfer claims and the complaints containing only Vanlev claims to the USDC for the District of New Jersey. All non-Vanlev cases and all non-Vanlev claims, including all such claims alleged in the complaint in the actions pending in the USDC for Southern District of New York were ordered to remain in the Southern District of New York. <br><br> The Class Members were allegedly damaged by the artificial inflation of Bristol Myers's stock price due to the defendants' materially false and misleading statements and omissions regarding the company's financial condition and the prospect for the U.S. Food and Drug Administration's approval of the drug Erbitux, in which Bristol-Myers invested $2 billion for the drug's development. <br><br> More specifically, the original complaint alleges that defendants violated the federal securities laws by making itself, and allowing its drug development partner to make, without correction, materially false and misleading statements about the progress of its Erbitux cancer treatment drug's application for FDA approval even as BRISTOL-MYERS knew that the application and data were false. Specifically, the complaint alleges that on December 28, 2001, a press release disclosed that the FDA had rejected the filing of a Biologics License Application for Erbitux. On January 4, 2002, The Cancer Letter reported that the FDA repeatedly informed defendants about problems with the Erbitux clinical trials during the Class Period. These shocking revelations caused the stock to plummet from a Class Period high of $56 to $40 by March of 2002.<br> <HR WIDTH=50% ALIGN=left> INDUSTRY CLASSIFICATION:<br> <b>SIC Code:</b> 2834<br> <b>Sector:</b> Healthcare<br> <b>Industry:</b> Major Drugs<br> </font><p></P><HR> <TABLE width='100%'> <TR> <TD ALIGN='left' width='30%'><font FACE=Garmond,Helvetica,Times size=1 color=#330066><B> COMPANY/ISSUER NAME:</B></font></TD> <TD ALIGN='left'><font FACE=Garmond,Helvetica,Times size=2 color=#330066><B> Bristol Myers Squibb Company</B></font></TD> </TR> <TR> <TD ALIGN='left' width='30%'><font FACE=Garmond,Helvetica,Times size=1 color=#330066><B> COMPANY/ISSUER TICKER:</B></font></TD> <TD ALIGN='left'><font FACE=Garmond,Helvetica,Times size=2 color=#330066><B> BMY</B></font></TD> </TR> <TR> <TD ALIGN='left' width='30%'><font FACE=Garmond,Helvetica,Times size=1 color=#330066><B> COMPANY WEBSITE:</B></font></TD> <TD ALIGN='left'><font FACE=Garmond,Helvetica,Times size=2 color=#330066><B> <A HREF='http://www.bms.com/'>http://www.bms.com/</A></B></font></TD> </TR> </TABLE><HR> <TABLE BORDER=0 width=100%> <TR><TD COLSPAN = 4><B><font FACE=Garmond,Helvetica,Times size=2 color=#330066> FIRST IDENTIFIED COMPLAINT IN THE DATABASE</font></B></TD></TR> <TR><TD colspan=4 align='left' bgcolor='#330066'> <font FACE=Garmond,Helvetica,Times size=2 color=#FFFFFF><B>Ira Gaines, et al. v. Bristol-Myers Squibb Co., et al.</B></font></TD></TR> <TR><TD align='left' colspan='4'><div align='left'> <table width='100%' CELLPADDING='0' CELLSPACING='0' BORDER='1'> <TR><TD align='left'><font FACE=Garmond,Helvetica,Times size=2 color=#330066> &nbsp;COURT:&nbsp;<b>S.D. New York</b></font></TD> <TD ALIGN='left'><font FACE=Garmond,Helvetica,Times size=2 color=#330066> &nbsp;DOCKET NUMBER:&nbsp;<b>02-CV-2251</b><font></font></font></TD></TR> <TR><TD align='left' colspan=2 bgcolor='#DDDDDD'> <font FACE=Garmond,Helvetica,Times size=2 color=#330066> &nbsp;JUDGE NAME:&nbsp;<b>Hon. Loretta A. Preska</b></font></TD></TR> <TR><TD align='left'><font FACE=Garmond,Helvetica,Times size=2 color=#330066> &nbsp;DATE FILED:&nbsp;<b>03/22/2002</b></font></TD> <TD align='left'><font FACE=Garmond,Helvetica,Times size=2 color=#330066> &nbsp;SOURCE:&nbsp;<b>Complaint<b></b></b></font></TD></TR> <TR><TD align='left' bgcolor='#DDDDDD'> <font FACE=Garmond,Helvetica,Times size=2 color=#330066> &nbsp;CLASS PERIOD START:&nbsp;<b>09/25/2001<b></b></b></font></td> <TD align='left' bgcolor='#DDDDDD'> <font FACE=Garmond,Helvetica,Times size=2 color=#330066> &nbsp;CLASS PERIOD END:&nbsp;<b>03/19/2002</b></font></TD></TR> <TR><TD align='left' colspan=2><font FACE=Garmond,Helvetica,Times size=2 color=#330066> &nbsp;TYPE OF COMPLAINT:&nbsp;<b>Unamended/Unconsolidated</b></font></TD></TR> <TR><TD align='left' colspan=2 bgcolor='#DDDDDD'> <font FACE=Garmond,Helvetica,Times size=2 color=#330066> &nbsp;PLAINTIFF FIRMS IN THIS OR SIMILAR CASE:</font></TD></TR> <TR><TD align='left' colspan=2><font FACE=Garmond,Helvetica,Times size=2 color=#330066><LI> <A HREF='http://www.a-g-s.com'>Abbey Gardy, LLP</A><BR>&nbsp;&nbsp;212 East 39th Street, New York, NY, 10016<BR> &nbsp;&nbsp; (voice) 212.889.3700, (fax) , info@abbeygardy.com <LI> <A HREF='http://www.bergermontague.com/'>Berger & Montague PC</A><BR>&nbsp;&nbsp;1622 Locust Street, Philadelphia, PA, 19103<BR> &nbsp;&nbsp; (voice) 800.424.6690, (fax) 215.875.4604, investorprotect@bm.net <LI> <A HREF='http://www.cauleygeller.com'>Cauley Geller Bowman Coates & Rudman LLP (Little Rock, AR)</A><BR>&nbsp;&nbsp;P.O. Box 25438, Little Rock, AR, 72221-5438<BR> &nbsp;&nbsp; (voice) 501.312.8500, (fax) 501.312.8505, <LI> <A HREF='http://www.cmht.com'>Cohen Milstein Hausfeld & Toll PLLC (Seattle WA)</A><BR>&nbsp;&nbsp;701 Fifth Avenue, Suite 6860, Seattle, WA, 98014<BR> &nbsp;&nbsp; (voice) 206.521.0080, (fax) 206.521.0166, lawinfo@cmht.com <LI> <A HREF='http://www.emersonpoynter.com'>Emerson Poynter LLP</A><BR>&nbsp;&nbsp;2228 Cottondale Avenue, Suite 100, Little Rock, AR, 72202<BR> &nbsp;&nbsp; (voice) 800.663.9817, (fax) 501.907.2556, epllp@emersonpoynter.com <LI> <A HREF='http://www.glancylaw.com/'>Glancy and Binkow</A><BR>&nbsp;&nbsp;1801 Avenue of the Stars, suite 311, Los Angeles, CA, 90067<BR> &nbsp;&nbsp; (voice) 310-201-9150, (fax) , info@glancylaw.com <LI> <A HREF='http://www.glrs.com/'>Goodkind Labaton Rudoff & Sucharow LLP</A><BR>&nbsp;&nbsp;100 Park Avenue, New York, NY, 10017<BR> &nbsp;&nbsp; (voice) 212.907.0700, (fax) 212.818.0477, info@glrslaw.com <LI> <A HREF=''>Law Offices of Charles J. Piven, P.A.</A><BR>&nbsp;&nbsp;World Trade Center-Baltimore,401 East Pratt Suite 2525, Baltimore, MD, 21202<BR> &nbsp;&nbsp; (voice) 410.332.0030, (fax) , pivenlaw@erols.com <LI> <A HREF='http://www.milberg.com'>Milberg Weiss Bershad Hynes & Lerach LLP (New York, NY)</A><BR>&nbsp;&nbsp;One Pennsylvania Plaza, New York, NY, 10119-1065<BR> &nbsp;&nbsp; (voice) 212.594.5300, (fax) , <LI> <A HREF=''>Much, Shelist, Freed, Denenberg, Ament & Eiger, P.C.</A><BR>&nbsp;&nbsp;200 N LaSalle St Ste 2100, Chicago, IL, 60601<BR> &nbsp;&nbsp; (voice) 312.346.3100, (fax) , <LI> <A HREF='http://www.snlaw.net/'>Schatz & Nobel, P.C.</A><BR>&nbsp;&nbsp;330 Main Street, Hartford, CT, 06106<BR> &nbsp;&nbsp; (voice) 800.797.5499, (fax) 860.493.6290, sn06106@AOL.com <LI> <A HREF='http://www.sbclasslaw.com'>Schiffrin & Barroway LLP</A><BR>&nbsp;&nbsp;3 Bala Plaza E, Bala Cynwyd, PA, 19004<BR> &nbsp;&nbsp; (voice) 610.667.7706, (fax) 610.667.7056, info@sbclasslaw.com <LI> <A HREF='http://www.whesq.com'>Wechsler Harwood LLP</A><BR>&nbsp;&nbsp;488 Madison Avenue 8th Floor, New York, NY, 10022<BR> &nbsp;&nbsp; (voice) 212.935.7400, (fax) , info@whhf.com <LI> <A HREF='http://www.wyca.com'>Weiss & Yourman (New York, NY)</A><BR>&nbsp;&nbsp;The French Building, 551 Fifth Ave., Suite 1600, New York, NY, 10126<BR> &nbsp;&nbsp; (voice) 212.682.3025, (fax) 212.682.3010, info@wyca.com <LI> <A HREF='http://www.whafh.com/'>Wolf Haldenstein Adler Freeman & Herz LLP</A><BR>&nbsp;&nbsp;270 Madison Avenue, New York, NY, 10016<BR> &nbsp;&nbsp; (voice) 212.545.4600, (fax) 212.686.0114, newyork@whafh.com <BR> <font face='Garmond,Helvetica,Times' size=1 color='#330066'> _____________________________________________ </font><BR> &nbsp;TOTAL NUMBER OF PLAINTIFF FIRMS:&nbsp; <b>15</b></font></TD></tr> </table></div> </TD></TR> </TABLE> <BR> <TABLE CELLPADDING=0 CELLSPACING=0 BORDER=1 width=100%> <TR><TD COLSPAN=4 bgcolor=#330066><font FACE=Garmond,Helvetica,Times size=2 color=#FFFFFF> &nbsp;DOCUMENTS FOR THE FIRST IDENTIFIED COMPLAINT</font></TD></TR><TR> <TD COLSPAN=4 bgcolor=#DDDDDD><font FACE=Garmond,Helvetica,Times size=2 color=#330066><b><A HREF='//'></A></b></font> </TD> </TR> <TR> <TD COLSPAN=2 align='left'><font FACE=Garmond,Helvetica,Times size=2 color=#330066>Type:&nbsp;</font> </TD> <TD COLSPAN=2 align='left'><font FACE=Garmond,Helvetica,Times size=2 color=#330066>Date on the document:&nbsp;</font> </TD> </TR></TABLE><TABLE BORDER=0 width=100%> <TR><TD COLSPAN = 4> <font FACE=Garmond,Helvetica,Times size=2 color=#330066><b> <HR>REFERENCE COMPLAINT</b></font></TD></TR> <TR><TD colspan=4 align='left' bgcolor='#330066'> <font FACE=Garmond,Helvetica,Times size=2 color=#FFFFFF> <b>In Re: Bristol-Myers Squibb Securities Litigation </b></font></TD></TR> <TR><TD align='left' colspan='4'><div align='left'> <table width='100%' CELLPADDING='0' CELLSPACING='0' BORDER='1'> <TR><TD align='left'><font FACE=Garmond,Helvetica,Times size=2 color=#330066> &nbsp;COURT:&nbsp;<b>S.D. New York</b></font></TD> <TD align='left'><font FACE=Garmond,Helvetica,Times size=2 color=#330066> &nbsp;DOCKET NUMBER:&nbsp;<b>02-CV-2251</b></font></TD></TR> <TR><TD align='left' colspan=2 bgcolor='#DDDDDD'> <font FACE=Garmond,Helvetica,Times size=2 color=#330066> &nbsp;JUDGE NAME:&nbsp;<b>Hon. Loretta A Preska</b></font></TD></TR> <TR><TD align='left'><font FACE=Garmond,Helvetica,Times size=2 color=#330066> &nbsp;DATE FILED:&nbsp<b>04/11/2003</b></font></TD> <TD align='left'><font FACE=Garmond,Helvetica,Times size=2 color=#330066> &nbsp;SOURCE:&nbsp;<b>Business Wires</b></font></TD></TR> <TR><TD align='left' bgcolor='#DDDDDD'> <font FACE=Garmond,Helvetica,Times size=2 color=#330066> &nbsp;CLASS PERIOD START:&nbsp;<b>10/19/1999</b></font></TD> <TD align='left' bgcolor='#DDDDDD'><font FACE=Garmond,Helvetica,Times size=2 color=#330066> &nbsp;CLASS PERIOD END:&nbsp;<b>03/10/2003</b></font></TD></TR> <TR><TD align='left' colspan=2><font FACE=Garmond,Helvetica,Times size=2 color=#330066> &nbsp;TYPE OF COMPLAINT:&nbsp;<b>Consolidated and/or Amended</b></font></TD></TR> <TR><TD align='left' colspan=2 bgcolor='#DDDDDD'> <font FACE=Garmond,Helvetica,Times size=2 color=#330066> &nbsp;PLAINTIFF FIRMS NAMED IN COMPLAINT:</font></TD></TR> <TR><TD align='left' colspan=2><font FACE=Garmond,Helvetica,Times size=2 color=#330066><LI> <A HREF='http://www.bermanesq.com'>Berman DeValerio Pease Tabacco Burt & Pucillo (MA)</A><BR>&nbsp;&nbsp;One Liberty Square, Boston, MA, 2109<BR> &nbsp;&nbsp; (voice) 617.542.8300, (fax) 617.230.0903, info@bermanesq.com <LI> <A HREF='http://www.blbglaw.com/'>Bernstein Litowitz Berger & Grossmann LLP (New York, NY)</A><BR>&nbsp;&nbsp;1285 Avenue of the Americas, 33rd Floor, New York, NY, 10019<BR> &nbsp;&nbsp; (voice) 212.554.1400, (fax) 212.554.1444, blbg@blbglaw.com <LI> <A HREF='http://www.milberg.com'>Milberg Weiss Bershad Hynes & Lerach LLP (New York, NY)</A><BR>&nbsp;&nbsp;One Pennsylvania Plaza, New York, NY, 10119-1065<BR> &nbsp;&nbsp; (voice) 212.594.5300, (fax) , <BR> <font face='Garmond,Helvetica,Times' size=1 color='#330066'> _____________________________________________ </font><BR> &nbsp;TOTAL NUMBER OF PLAINTIFF FIRMS:&nbsp; <b>3</b></font></TD></TR> </table></div> </TABLE><BR> <TABLE CELLPADDING=0 CELLSPACING=0 BORDER=1 width=100%> <TR><TD COLSPAN=4 bgcolor=#330066><font FACE=Garmond,Helvetica,Times size=2 color=#FFFFFF> &nbsp;DOCUMENTS FOR THE REFERENCE COMPLAINT</font></TD></TR><TR> <TD COLSPAN=4 bgcolor=#DDDDDD><font FACE=Garmond,Helvetica,Times size=2 color=#330066><b><A HREF='/1023/BMY02-01/20030411_r01c_022251.pdf'>Consolidated Class Action Complaint</A></b></font> </TD> </TR> <TR> <TD COLSPAN=2 align='left'><font FACE=Garmond,Helvetica,Times size=2 color=#330066>Type:&nbsp;Complaint</font> </TD> <TD COLSPAN=2 align='left'><font FACE=Garmond,Helvetica,Times size=2 color=#330066>Date on the document:&nbsp;04/11/2003</font> </TD> </TR><TR> <TD COLSPAN=4 bgcolor=#DDDDDD><font FACE=Garmond,Helvetica,Times size=2 color=#330066><b><A HREF='/1023/BMY02-01/20031020_r02k_022251.pdf'>US District Court Civil Docket</A></b></font> </TD> </TR> <TR> <TD COLSPAN=2 align='left'><font FACE=Garmond,Helvetica,Times size=2 color=#330066>Type:&nbsp;Docket</font> </TD> <TD COLSPAN=2 align='left'><font FACE=Garmond,Helvetica,Times size=2 color=#330066>Date on the document:&nbsp;10/20/2003</font> </TD> </TR><TR> <TD COLSPAN=4 bgcolor=#DDDDDD><font FACE=Garmond,Helvetica,Times size=2 color=#330066><b><A HREF='/1023/BMY02-01/200493_r05n_02CV2251.pdf'>Notice Of Pendency And Proposed Settlement Of Class Action </A></b></font> </TD> </TR> <TR> <TD COLSPAN=2 align='left'><font FACE=Garmond,Helvetica,Times size=2 color=#330066>Type:&nbsp;Notice</font> </TD> <TD COLSPAN=2 align='left'><font FACE=Garmond,Helvetica,Times size=2 color=#330066>Date on the document:&nbsp;09/03/2004</font> </TD> </TR><TR> <TD COLSPAN=4 bgcolor=#DDDDDD><font FACE=Garmond,Helvetica,Times size=2 color=#330066><b><A HREF='/1023/BMY02-01/200493_r06x_02CV2251.pdf'>Proof of Claim and Release</A></b></font> </TD> </TR> <TR> <TD COLSPAN=2 align='left'><font FACE=Garmond,Helvetica,Times size=2 color=#330066>Type:&nbsp;Other</font> </TD> <TD COLSPAN=2 align='left'><font FACE=Garmond,Helvetica,Times size=2 color=#330066>Date on the document:&nbsp;09/03/2004</font> </TD> </TR><TR> <TD COLSPAN=4 bgcolor=#DDDDDD><font FACE=Garmond,Helvetica,Times size=2 color=#330066><b><A HREF='/1023/BMY02-01/2005325_r04k_02CV2251.pdf'>U.S. District Court Civil Docket</A></b></font> </TD> </TR> <TR> <TD COLSPAN=2 align='left'><font FACE=Garmond,Helvetica,Times size=2 color=#330066>Type:&nbsp;Docket</font> </TD> <TD COLSPAN=2 align='left'><font FACE=Garmond,Helvetica,Times size=2 color=#330066>Date on the document:&nbsp;05/16/2006</font> </TD> </TR></TABLE><BR> <TABLE CELLPADDING=0 CELLSPACING=0 BORDER=1 width=100%><TR><TD COLSPAN=4 bgcolor=#330066><font FACE=Garmond,Helvetica,Times size=2 color=#FFFFFF> &nbsp;OTHER DOCUMENTS</font></TD></TR><TR><TD COLSPAN=4 bgcolor=#DDDDDD> <font FACE=Garmond,Helvetica,Times size=2 color=#330066><b> <A HREF='/1023/BMY02-01/20020322_o01c_Jrslwz.pdf'>Class Action Complaint For Violation Of Federal Securities Laws</A></b></font></TD></TR> <TR><TD COLSPAN=4 align='left'> <font FACE=Garmond,Helvetica,Times size=2 color=#330066> Case Name and/or Number:&nbsp;Jaroslawicz</font> </TD></TR> <TR> <TD COLSPAN=2 align='left'> <font FACE=Garmond,Helvetica,Times size=2 color=#330066> Type:&nbsp;Complaint</font></TD> <TD COLSPAN=2 align='left'> <font FACE=Garmond,Helvetica,Times size=2 color=#330066> Date on the document:&nbsp;03/22/2002</font></TD> </TR></TABLE> <font FACE=Garmond,Helvetica,Times size=2 color=#330066> <HR><b>WARNING AND DISCLAIMER OF LIABILITY:</b><br> The information included on this Web site, whether provided by personnel employed by Stanford Law School or by third parties, is provided for research and teaching purposes only. Neither Stanford University, Stanford Law School, nor any of their employees, agents, contractors, or affiliates warrant the accuracy or completeness of the information or analyses displayed herein, and we caution all readers that inclusion of any information on this site does not constitute an endorsement of the truthfulness or accuracy of that information. In particular, this Web site contains complaints and other documents filed in federal and state courts, which make allegations that may or may not be accurate. No reader should, on the basis of information contained in or referenced by this Web site, assume that any of these allegations are truthful. <HR> </font> <font FACE=Garmond,Helvetica,Times size=1 color=#330066> Go to <A HREF='/search.shtml'> <font FACE=Garmond,Helvetica,Times size=1 color=#330066>Search</font></A> &nbsp;page |</font> <font FACE=Garmond,Helvetica,Times size=1 color=#330066> Go to <A HREF='/companies.html'> <font FACE=Garmond,Helvetica,Times size=1 color=#330066>Case Index</font></A> &nbsp;page |</font> <font FACE=Garmond,Helvetica,Times size=1 color=#330066> Back to <A HREF=#top><font FACE=Garmond,Helvetica,Times size=1 color=#330066> Top</font></A><BR><BR></font><BR> </TD></TR></TABLE></BODY></HTML>